Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pathogens (R01)

The summary for the Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pathogens (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pathogens (R01)
	CFDA Number:	93.856
	CFDA Description:	Microbiology and Infectious Diseases Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-AI-10-010
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	May 03, 2010
	Creation Date:	May 03, 2010
	Original Closing Date for Applications:	Jul 08, 2010
	Current Closing Date for Applications:	Jul 08, 2010
	Archive Date:	Aug 08, 2010
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	$300,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), invites research applications in support of preclinical development of lead candidate therapeutics against Nesseria gonorrhoeae, Hepatitis B Virus and Clostridium difficile. Mechanism of Support. This FOA will utilize the R01 award mechanism. Funds Available and Anticipated Number of Awards. The NIAID intends to commit $6 million in total costs in FY2011 to fund 6-10 applications in response to this FOA.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-ai-10-010.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Biomedical Prevention of HIV Research Education (R25); • Partnerships for Next Generation Biodefense Diagnostics (R01); • National Biocontainment Laboratories (NBLs) Operations Support Limited Competition (UC7); • International Extramural Associates Research Development Awards (IEARDA) [G11]; • Non-Antibiotic Selectable Markers for Biodefense (R21); • Partnerships to Improve Diagnosis and Treatment of Selected Drug-Resistant Healthcare-Associated Inf...; • Cooperative Research Partnerships for Biodefense (U01); • Pharmacological Approaches to Combating Antimicrobial Resistance (R01); • Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) [U54]